Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation


Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral genes relative to the viral promoter (aka promoter-proximal attenuation). The gene shifts can be constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome. Viral replication can increase or decrease depending on the position of expressed viral gene and depending on the nature and degree of the positional shift. Viral gene rearrangements are selected to maintain sufficient non-infectious replication of RSV while eliciting host anti-RSV immune responses. Viral genes targeted for such rearrangement include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or genome segment.

One modification of particular interest is the placement of the G and F protective antigen genes in a promoter-proximal position for increased expression. The gene position-shifted RSV can be further manipulated by the addition of specific nucleotide and amino acid point mutations or host range restriction determinants to yield desired phenotypic and structural effects.

Potential Commercial Applications: Competitive Advantages:
  • Infectious Disease - Respiratory Syncytial Virus
  • Vaccines
  • Therapeutics
  • Prophylactics
  • Childhood Vaccines
 


Inventors:

Christine Krempl (NIAID)  ➽ more inventions...

Peter Collins (NIAID)  ➽ more inventions...

Brian Murphy (NIAID)  ➽ more inventions...

Ursula Buchholz
Stephen Whitehead (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,923,971 issued 2005-08-02
U.S. Pat: 7,662,397 issued 2010-02-16
U.S. Pat: 7,744,902 issued 2010-06-29
U.S. Pat: 2001268709 issued 2007-01-11
U.S. Pat: 1294858 issued 2008-12-03
U.S. Pat: 153530 issued 2011-02-01
U.S. Pat: 10-0899030 issued 2009-05-15
U.S. Pat: 266418 issued 2009-04-29
EP Application No. 01946696.0
IL Application No. 153530
JP Application No. 10-2002-505815
KR Application No. 10-2002-7017577
MX Application No. 2002-012818
US Application No. 60/213,708
US Application No. 10/312,191

Publications:
C Krempl et al. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol. 2002 Dec;76(23):11931-11942. PubMed abs
Y Aloni, N Hay. Attenuation may regulate gene expression in animal viruses and cells. CRC Crit Rev Biochem. 1985;18(4):327-383. PubMed abs

Collaboration Opportunity:

The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize live attenuated vaccines. Please contact Michael Piziali at 301-451-3527 for more information.


Licensing Contact:
Peter Soukas, J.D.
Email: peter.soukas@nih.gov
Phone: 301-496-2644

OTT Reference No: E-225-2000-0
Updated: Sep 1, 2008